OTCMKTS:WCUI

Wellness Center USA Competitors

$0.06
0.00 (0.00 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
Now: $0.06
$0.06
50-Day Range
$0.04
MA: $0.05
$0.06
52-Week Range
$0.02
Now: $0.06
$0.18
Volume14,135 shs
Average Volume61,887 shs
Market Capitalization$6.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.57

Competitors

Wellness Center USA (OTCMKTS:WCUI) Vs. MATN, BNTC, MNKKQ, SXTC, AMAR, and MLND

Should you be buying WCUI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Wellness Center USA, including Mateon Therapeutics (MATN), Benitec Biopharma (BNTC), Mallinckrodt (MNKKQ), China SXT Pharmaceuticals (SXTC), Amarillo Biosciences (AMAR), and Millendo Therapeutics (MLND).

Wellness Center USA (OTCMKTS:WCUI) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Wellness Center USA and Mateon Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
Mateon Therapeutics00103.00

Mateon Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 971.43%. Given Mateon Therapeutics' higher possible upside, analysts plainly believe Mateon Therapeutics is more favorable than Wellness Center USA.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are owned by institutional investors. Comparatively, 0.0% of Mateon Therapeutics shares are owned by institutional investors. 14.1% of Wellness Center USA shares are owned by company insiders. Comparatively, 39.2% of Mateon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Wellness Center USA and Mateon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
Mateon TherapeuticsN/A-64.66%-42.92%

Valuation & Earnings

This table compares Wellness Center USA and Mateon Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00213.00$-2,390,000.00N/AN/A
Mateon TherapeuticsN/AN/A$-6,640,000.00N/AN/A

Wellness Center USA has higher revenue and earnings than Mateon Therapeutics.

Risk & Volatility

Wellness Center USA has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Summary

Mateon Therapeutics beats Wellness Center USA on 5 of the 9 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Volatility and Risk

Wellness Center USA has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Wellness Center USA and Benitec Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
Benitec Biopharma01002.00

Benitec Biopharma has a consensus target price of $14.00, suggesting a potential upside of 168.71%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Wellness Center USA.

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are held by institutional investors. Comparatively, 5.7% of Benitec Biopharma shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 1.0% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Wellness Center USA and Benitec Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
Benitec BiopharmaN/AN/AN/A

Earnings & Valuation

This table compares Wellness Center USA and Benitec Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00213.00$-2,390,000.00N/AN/A
Benitec Biopharma$100,000.00251.02$-8,270,000.00($8.10)-0.64

Wellness Center USA has higher earnings, but lower revenue than Benitec Biopharma.

Summary

Benitec Biopharma beats Wellness Center USA on 6 of the 8 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and Mallinckrodt (OTCMKTS:MNKKQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Volatility and Risk

Wellness Center USA has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.82, indicating that its share price is 282% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Wellness Center USA and Mallinckrodt, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
Mallinckrodt0000N/A

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are held by institutional investors. Comparatively, 51.7% of Mallinckrodt shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 3.1% of Mallinckrodt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Wellness Center USA and Mallinckrodt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
Mallinckrodt-83.44%46.40%6.94%

Earnings & Valuation

This table compares Wellness Center USA and Mallinckrodt's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00213.00$-2,390,000.00N/AN/A
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03

Wellness Center USA has higher earnings, but lower revenue than Mallinckrodt.

Summary

Mallinckrodt beats Wellness Center USA on 5 of the 9 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are held by institutional investors. Comparatively, 8.9% of China SXT Pharmaceuticals shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Wellness Center USA and China SXT Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
China SXT Pharmaceuticals0000N/A

Volatility & Risk

Wellness Center USA has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

Profitability

This table compares Wellness Center USA and China SXT Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
China SXT PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Wellness Center USA and China SXT Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00213.00$-2,390,000.00N/AN/A
China SXT Pharmaceuticals$5.16 million4.45$-10,290,000.00N/AN/A

Wellness Center USA has higher earnings, but lower revenue than China SXT Pharmaceuticals.

Summary

Wellness Center USA beats China SXT Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Wellness Center USA and Amarillo Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00213.00$-2,390,000.00N/AN/A
Amarillo Biosciences$10,000.002,098.67$-1,580,000.00N/AN/A

Amarillo Biosciences has lower revenue, but higher earnings than Wellness Center USA.

Profitability

This table compares Wellness Center USA and Amarillo Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
Amarillo Biosciences-7,434.30%N/A-320.19%

Volatility & Risk

Wellness Center USA has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Wellness Center USA and Amarillo Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
Amarillo Biosciences0000N/A

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Wellness Center USA beats Amarillo Biosciences on 5 of the 8 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares Wellness Center USA and Millendo Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00213.00$-2,390,000.00N/AN/A
Millendo TherapeuticsN/AN/A$-44,570,000.00($3.25)-0.33

Wellness Center USA has higher revenue and earnings than Millendo Therapeutics.

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are owned by institutional investors. Comparatively, 41.1% of Millendo Therapeutics shares are owned by institutional investors. 14.1% of Wellness Center USA shares are owned by company insiders. Comparatively, 3.7% of Millendo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Wellness Center USA has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Wellness Center USA and Millendo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
Millendo TherapeuticsN/A-83.79%-67.06%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Wellness Center USA and Millendo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
Millendo Therapeutics04202.33

Millendo Therapeutics has a consensus price target of $3.80, indicating a potential upside of 251.85%. Given Millendo Therapeutics' higher probable upside, analysts plainly believe Millendo Therapeutics is more favorable than Wellness Center USA.

Summary

Millendo Therapeutics beats Wellness Center USA on 5 of the 9 factors compared between the two stocks.


Wellness Center USA Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Mateon Therapeutics logo
MATN
Mateon Therapeutics
1.5$0.28flat$25.27 millionN/A0.00
Benitec Biopharma logo
BNTC
Benitec Biopharma
1.2$5.21flat$25.10 million$100,000.00-0.64Increase in Short Interest
Mallinckrodt logo
MNKKQ
Mallinckrodt
0.8$0.29flat$24.42 million$3.16 billion-0.01
SXTC
China SXT Pharmaceuticals
0.4$1.48flat$22.96 million$5.16 million0.00
AMAR
Amarillo Biosciences
0.5$0.50flat$20.99 million$10,000.000.00
Millendo Therapeutics logo
MLND
Millendo Therapeutics
1.5$1.08flat$20.57 millionN/A-0.45Increase in Short Interest
Artelo Biosciences logo
ARTL
Artelo Biosciences
1.2$1.27flat$19.95 millionN/A-1.26Earnings Announcement
News Coverage
Gap Up
Xenetic Biosciences logo
XBIO
Xenetic Biosciences
1.5$2.19flat$19.16 million$20,000.000.00Decrease in Short Interest
News Coverage
AngioSoma logo
SOAN
AngioSoma
1.0$0.04flat$19.03 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Bellicum Pharmaceuticals logo
BLCM
Bellicum Pharmaceuticals
1.3$3.51flat$17.76 million$7.14 million-0.26
NTN Buzztime logo
NTN
NTN Buzztime
0.4$5.94flat$17.68 million$19.81 million-2.88News Coverage
Gap Up
Sonoma Pharmaceuticals logo
SNOA
Sonoma Pharmaceuticals
0.5$8.31flat$17.26 million$18.94 million-9.34Increase in Short Interest
XTLB
XTL Biopharmaceuticals
0.6$3.24flat$16.65 millionN/A-5.23Decrease in Short Interest
News Coverage
Eledon Pharmaceuticals logo
ELDN
Eledon Pharmaceuticals
1.6$11.43flat$16.41 millionN/A-0.51
Novus Therapeutics logo
NVUS
Novus Therapeutics
1.4$11.43flat$16.41 millionN/A-0.51
NMUS
Nemus Bioscience
0.6$0.12flat$16.20 millionN/A0.00High Trading Volume
Gap Down
Intec Pharma logo
NTEC
Intec Pharma
1.4$4.06flat$14.58 millionN/A-0.57
NVLNF
Novelion Therapeutics
0.6$0.70flat$13.77 million$130.43 million0.00Gap Down
Medicure logo
MCUJF
Medicure
0.6$1.32flat$13.53 million$15.20 million-1.05Decrease in Short Interest
News Coverage
MedAvail logo
MDVL
MedAvail
1.9$13.20flat$13.41 million$1.03 million-3.23Analyst Report
Increase in Short Interest
NRIFF
Nuvo Pharmaceuticals
0.7$1.14flat$13.00 million$52.41 million28.50Gap Up
Teligent logo
TLGT
Teligent
1.2$0.58flat$12.62 million$65.90 million-0.07News Coverage
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.25flat$12.29 millionN/A-0.48Decrease in Short Interest
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.25flat$12.29 millionN/A-0.48Decrease in Short Interest
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08flat$11.99 millionN/A-3.90Decrease in Short Interest
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.67flat$11.46 millionN/A-0.89Increase in Short Interest
Gap Up
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.15flat$11.36 millionN/A0.00
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04flat$10.81 million$7.38 million0.00Gap Down
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12flat$10.76 million$4.08 million-1.28Increase in Short Interest
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.14flat$9.87 millionN/A0.00Gap Up
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.53flat$8.77 millionN/A0.00Gap Down
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00Decrease in Short Interest
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08flat$7.15 millionN/A0.00News Coverage
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.32flat$7.07 million$2.66 million-10.67Gap Up
Bioxytran logo
BIXT
Bioxytran
0.0$0.07flat$7.05 millionN/A0.00Gap Up
KAYS
Kaya
0.7$0.43flat$6.23 million$1.01 million0.00Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23flat$5.46 million$3.48 million-1.92News Coverage
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72flat$5.43 million$9.47 million0.00
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11flat$4.38 million$3.65 million0.00Decrease in Short Interest
Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$4.05 millionN/A0.00Increase in Short Interest
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.50 millionN/A0.00Increase in Short Interest
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17flat$3.47 millionN/A0.00High Trading Volume
Increase in Short Interest
Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.84 millionN/A-0.09
NSPX
Inspyr Therapeutics
0.5$0.02flat$2.31 millionN/A0.00Gap Down
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.